HIGHLIGHTS
- who: from the point therapies (ICT have published the paper: OPEN ACCESS, in the Journal: (JOURNAL) of 08/04/2023
- what: The authors report the novel VEGFR-3 inhibitor EVT801 that presents a more selective and less toxic profile than two ma- to either single treatment. The authors focused the analysis on kidney cancer because Downloaded from http://aacrjournals.org/cancerrescommun/article-pdf/2/11/1504/3285097/crc-22-0151.pdf by guest on 08 April 2023 AACRJournals.org Cancer Res Commun; 2(11) November 2022 kidney tumor. Taken together, the research demonstrates a novel . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.